Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. COYA
stocks logo

COYA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.23M
+62756.92%
-0.377
+109.26%
156.00K
-39.51%
-0.445
+1.14%
--
--
-0.420
+16.67%
Estimates Revision
The market is revising Upward the revenue expectations for Coya Therapeutics, Inc. (COYA) for FY2025, with the revenue forecasts being adjusted by 27.43% over the past three months. During the same period, the stock price has changed by -4.31%.
Revenue Estimates for FY2025
Revise Upward
up Image
+27.43%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-18.26%
In Past 3 Month
Stock Price
Go Down
down Image
-4.31%
In Past 3 Month
Wall Street analysts forecast COYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COYA is 17.50 USD with a low forecast of 15.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast COYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COYA is 17.50 USD with a low forecast of 15.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.000
sliders
Low
15.00
Averages
17.50
High
20.00
Current: 6.000
sliders
Low
15.00
Averages
17.50
High
20.00
Lake Street
Buy
maintain
$16 -> $17
2025-11-05
Reason
Lake Street
Price Target
$16 -> $17
2025-11-05
maintain
Buy
Reason
Lake Street raised the firm's price target on Coya Therapeutics to $17 from $16 and keeps a Buy rating on the shares after the company released preclinical in vivo neuroinflammation data for COYA-303 consistent with earlier in vitro preclinical results released by Coya.
Lake Street
NULL -> Buy
initiated
$16
2025-07-09
Reason
Lake Street
Price Target
$16
2025-07-09
initiated
NULL -> Buy
Reason
Lake Street initiated coverage of Coya Therapeutics with a Buy rating and $16 price target. The firm says the company's anti-inflammation platform utilizes a disease pathway agnostic approach to increase the number and function of regulatory T cells. The evidence supporting a therapeutic anti-inflammatory benefit of Coya's low dose IL-2 is strong, the analyst tells investors in a research note.
Lucid Capital
Elemer Piros
Buy
initiated
$20
2025-06-09
Reason
Lucid Capital
Elemer Piros
Price Target
$20
2025-06-09
initiated
Buy
Reason
Lucid Capital analyst Elemer Piros initiated coverage of Coya Therapeutics with a Buy rating and $20 price target. Coya is developing a pioneering approach to treat neurodegenerative disorders by addressing inflammation in the brain, the analyst tells investors in a research note. The firm sees an unmet need in amyotrophic lateral sclerosis.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$18
2025-04-22
Reason
D. Boral Capital
Jason Kolbert
Price Target
$18
2025-04-22
Maintains
Strong Buy
Reason
Atea Pharmaceuticals (AVIR) announced the appointment of Howard Berman, Ph.D. to its Board of Directors. Dr. Berman will serve as a non-voting observer to the Board through Atea's 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. The Company is adding Dr. Berman to the Board as part of its entry into an agreement with Bradley Radoff and Michael Torok. In connection with the Agreement, the Radoff-JEC Group has withdrawn its slate of nominated director candidates and has agreed to vote all of the shares it collectively owns in favor of each of Atea's Board nominees at the 2025 Annual Meeting. The Company also announced that Franklin Berger has informed the Company of his intention not to stand for reelection at Atea's 2027 Annual Meeting of Stockholders. Berman, Ph.D., is the Founder, Executive Chairman and former CEO of Coya Therapeutics (COYA).
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$18
2025-03-27
Reason
D. Boral Capital
Jason Kolbert
Price Target
$18
2025-03-27
Maintains
Strong Buy
Reason
Chardan Capital
Keay Nakae
Strong Buy
Maintains
$14
2025-03-20
Reason
Chardan Capital
Keay Nakae
Price Target
$14
2025-03-20
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Coya Therapeutics Inc (COYA.O) is -4.01, compared to its 5-year average forward P/E of -7.14. For a more detailed relative valuation and DCF analysis to assess Coya Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.14
Current PE
-4.01
Overvalued PE
1.72
Undervalued PE
-16.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.73
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.93
Undervalued EV/EBITDA
-4.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
18.80
Current PS
0.00
Overvalued PS
34.22
Undervalued PS
3.38
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

COYA News & Events

Events Timeline

(ET)
2025-11-12
08:18:45
Coya Therapeutics announces Q3 earnings per share of 13 cents, below consensus estimate of 30 cents.
select
2025-11-04 (ET)
2025-11-04
09:02:27
Coya Therapeutics Reveals Findings from In Vivo Animal Study of COYA 303
select
2025-10-24 (ET)
2025-10-24
06:33:39
Coya Therapeutics Sets Price for $3.64M Spot Secondary at $5.50
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-13Benzinga
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics with $15 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

[object Object]
Preview
8.5
10-24Newsfilter
Coya Therapeutics Reveals Pricing for Increased $20 Million Public Offering of Common Stock

  • Public Offering Announcement: Coya Therapeutics has priced an underwritten public offering of 3,636,364 shares of common stock at $5.50 per share, aiming to raise approximately $20 million for working capital and clinical development.

  • Underwriter and Closing Details: Lucid Capital Markets is the sole book-running manager for the offering, which is expected to close around October 27, 2025, pending customary closing conditions.

  • Company Overview: Coya Therapeutics, based in Houston, focuses on developing biologics to enhance regulatory T cell function for treating neurodegenerative disorders, with a pipeline that includes Treg-enhancing biologics and cell therapies.

  • Investigational Product COYA 302: COYA 302 is a proprietary biologic therapy aimed at treating ALS by enhancing Treg function and suppressing inflammation, currently being evaluated in a Phase 2 clinical trial.

[object Object]
Preview
8.5
10-24SeekingAlpha
Coya Therapeutics Declines Following $20M Stock Offering Announcement

  • Public Offering Details: Coya Therapeutics has announced a public offering of 3,636,364 shares priced at $5.50 each, aiming to raise approximately $20 million, with a potential additional 545,454 shares available to the underwriter.

  • Use of Proceeds: The company plans to utilize the net proceeds from the offering for working capital and general corporate purposes, including funding its clinical development plan.

  • Closing Timeline: The offering is expected to close around October 27, 2025, subject to standard closing conditions.

  • Market Reaction: Following the announcement, Coya Therapeutics' stock saw a premarket decline of 12.7%, trading at $6.09.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Coya Therapeutics Inc (COYA) stock price today?

The current price of COYA is 6 USD — it has decreased -2.44 % in the last trading day.

arrow icon

What is Coya Therapeutics Inc (COYA)'s business?

Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.

arrow icon

What is the price predicton of COYA Stock?

Wall Street analysts forecast COYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COYA is 17.50 USD with a low forecast of 15.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Coya Therapeutics Inc (COYA)'s revenue for the last quarter?

Coya Therapeutics Inc revenue for the last quarter amounts to 3.56M USD, decreased % YoY.

arrow icon

What is Coya Therapeutics Inc (COYA)'s earnings per share (EPS) for the last quarter?

Coya Therapeutics Inc. EPS for the last quarter amounts to -0.13 USD, decreased -50.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Coya Therapeutics Inc (COYA)'s fundamentals?

The market is revising Upward the revenue expectations for Coya Therapeutics, Inc. (COYA) for FY2025, with the revenue forecasts being adjusted by 27.43% over the past three months. During the same period, the stock price has changed by -4.31%.
arrow icon

How many employees does Coya Therapeutics Inc (COYA). have?

Coya Therapeutics Inc (COYA) has 8 emplpoyees as of December 05 2025.

arrow icon

What is Coya Therapeutics Inc (COYA) market cap?

Today COYA has the market capitalization of 125.55M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free